Back to News
Market Impact: 0.4
Roche: Enicepatide Shows Mean HbA1c Reduction Of 2.65% In Phase II Study At 48 Weeks
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Roche reported positive topline Phase II results for enicepatide (CT-388-104) in adults with type 2 diabetes and overweight or obesity. The drug met both primary endpoints and showed dose-dependent effects, supporting its clinical-development potential in the large diabetes and obesity treatment markets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.60
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- The AI ‘credit card’ is getting costlier as CoreWeave bond yield tops 16%
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal